AHEAD (AI-assisted Hematolgic AnalyticDecision Support)
Innovations AHEAD (AI-assisted Hematolgic AnalyticDecision Support)
  • Technology Introduction
We developed state-of-art artificial intelligence from retrospective data of acute leukemia patients to create two services:
  1. Residual disease detection: an advanced algorithm to perform multicolor flow cytometry analysis on bone marrow specimens of acute leukemia patients.
  2. Relapse and Mortality Prediction: a comprehensive risk stratification and outcome prediction models for acute myeloid leukemia patients using historical examination and treatment records.
 
  • Scientific Innovation
  1. The residual disease detection model could reduce the interpretation time from 20 minutes to 7 seconds for each sample with an accuracy of 90%
  2. The outcome prediction model could reach over 80% accuracy in next-3-month relapse and survival prediction.
 
  • This technology won the Futuretech Breakthrough Award in 2018 Future Tech Expo.
 
  • Institutes
National Tsing Hua University and National Taiwan University Hospital
Yu-Fen Wang/ahead.taiwan@gmail.com


 



本網站使用您的Cookie於優化網站及您的瀏覽經驗。繼續瀏覽網站即表示您同意本公司隱私權政策,您可至隱私權政策了解詳細資訊。